Mdxhealth files U.S. Shelf Registration on Form F-3

Shelf Registration on Form IRVINE CA and HERSTAL BELGIUM – December 19, 2022 - Mdxhealth SA, NASDAQ/Euronext MDXH), a commercial stage precision diagnostics company, announced today that it had filed a U.S. shelf' registration statement to register its American Depositary Shares, ('ADSs) each representing 10 ordinary shares
.

As a matter standard corporate procedure for NASDAQ listed companies, the Company filed the shelf register statement and associated financial information to facilitate any future strategic or financing requirements. The shelf registration statement can be kept available up to three years after it is declared effective. About mdxhealth(r). Mdxhealth, a commercial-stage precision diagnosis company, provides actionable molecular diagnostic data to personalize the treatment and diagnosis of cancer.
.

The Company's tests use proprietary genetic, epigenetic and other molecular technology to assist physicians in diagnosing urologic cancers. The European headquarters of the Company are located in Herstal in Belgium. There are laboratory operations in Nijmegen (The Netherlands) and Irvine, California. Additional laboratory operations can be found in Plano, Texas.
.

This press release contains forward looking statements and estimates regarding the future performance of MDxHealth, the market it operates in, and other factors. All of these involve risks and uncertainties. These statements can be made, but not always, by using words and phrases such as "potential", "expect", or "will", etc.
.

This release contains forward-looking statements, including statements about the acquisition of Oncotype(r) GPS prostate carcinoma business from Exact Sciences, statements regarding future operating results, statements regarding product development efforts, and statements regarding our strategies and positioning, resources, capabilities, and expectations for future events and performance. These statements and estimates are based upon assumptions and assessments made of known and unknown risk, uncertainties, and other factors. They may not be accurate. Actual events can be difficult to predict and could depend on factors beyond the control of the company. They may also turn out to have a materially different outcome.
.

Forward-looking statements can include statements regarding our future operating results, product developments, strategies, positioning, resources and capabilities, as well as statements about our expectations, performance, positioning, and other statements. There are many factors that could affect actual results, conditions, or events. These include the uncertainties related to the coronavirus pandemic (COVID-19), including its potential effects on our operations and demand for our product; our ability and willingness to market our products successfully and profitably by healthcare providers; our ability and willingness to pay for our products or services by health insurance companies and other payers; our ability and ability to obtain regulatory approvals and comply to applicable regulations; and the nature and amount of competition for our products or services. Additional risks and uncertainties can be found in the Risk Factors section of our latest Annual Report on Form 20F and other reports filed with Securities and Exchange Commission.
.

MDxHealth disclaims any obligation, except as required by law or regulation, to update forward-looking statements contained in this press release. This press release is not intended to be an invitation or offer for the sale or purchase securities or assets by MDxHealth. Without registration under the U.S. Securities Act, no securities of MDxHealth can be offered or sold in the United States.
.

Securities Act of 1933 as amended or in compliance with an exception therefrom and in accordance to any applicable U.S securities laws. NOTE: The trademarks and registered trademarks of MDxHealth SA include the mdxhealth logo.
.

All other trademarks or service marks remain the property of their respective owners.